Sarah Cannon Research Institute Sponsors Large-Scale Breast Cancer Trial

December 9, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

NASHVILLE, Tenn.--(BUSINESS WIRE)--The Sarah Cannon Research Institute will enroll 1,800 breast cancer patients for its TITAN study, a clinical research trial investigating the role of ixabepilone (Ixempra) in the treatment of early breast cancer.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Postmarket research